XavTrap® (XING anti-viral Trapping technology)
XavTrap is a recombinant platform technology using yeast cell fragments to rapidly express single-chain variable fragment (scFV), nanobodies or peptides for diagnostic applications. This platform technology can be rapidly made to target a specific disease (Disease X), including seasonal mutations of influenzas and coronavirus. Xing XavTrap® platform produces lead candidates 66% faster than cutting edge mammalian antibody pipelines, which XING has validated as part of the NIH-RADx Program*.
Xing novel, patented yeast cell wall fragment stably displaying multiple (10-15) VHVL domains
- Recombinant yeast cell wall fragment expressing fusion protein
- Full genetic control: Express scFvs, nanobodies, receptor proteins or antigens
- Multiplexable
- Multivalent display on cell wall scaffold to enhance avidity and sensitivity
- Rapid development
- Replacement for standard monoclonal antibody reagents
- Platform Technology with broad utility – ELISA, label-free electrochemical probes, lateral flow and other instant readout devices
- Broad diagnostic applicability including parasite, viral, immunomarkers and soluble cancer biomarkers
